Chairman & Registrar
Maureen Foulkes(-Hajdu) worked in the Marketing Department of her Father’s very successful scientific instrument manufacturing company (MSE Centrifuges Ltd.) for five years before leaving to change her career path to academia in Montreal, Canada. Initially, she worked for the Dean of Students at Sir George Williams University, and then as Personal Assistant to the Principal of the first English-speaking community college in Quebec, using her fluent French. On returning to the U.K. she worked briefly in the French Department at U.C.L. before landing the job of Registrar of the London Sloan Fellowship Programme at the London Business School (when the Principal was Prof. Sir James Ball, later to become a longstanding Trustee of the Foulkes Foundation). She was a founding Trustee of the Foulkes Foundation when her Father set it up in 1972, and also took on the role of Registrar in 1981; she became Chairman of the Foundation on her Father’s death in 1993. She is dedicated to preserving and enhancing her late Father’s legacy, and is fiercely protective of all the wonderful Fellows the Foundation has had the privilege of supporting over the years. Many of them have made a significant contribution in the fields of science and medicine to the benefit of mankind, and Ernest would certainly have been very proud of the success of his uniquely far-sighted vision.
Granddaughter of the Founder
Georgina graduated from University College London with a BSc in Geography and then moved to France to undertake her Masters in International Business at the Grenoble Graduate Business School. On her return to London, Georgina worked for the French Team at HSBC Investment Bank and then for the Economic Section of the French Embassy. In 2002 she moved to the Telecoms & Technology Division of IIR Conferences (part of the Informa Group) where she worked as a Conference Producer developing, project managing and hosting a number of overseas conferences. In 2007 she was promoted to Conference Director with responsibility for several event portfolios. In 2010, Georgina moved to IQPC, another conference company, where she was responsible for setting up a successful new business in a highly competitive market, and driving it forward to create a reputed market brand that was profitable after just two years. More recently, Georgina has been acting as a strategic consultant to charities and enjoying motherhood. Georgina is also a keen saxophonist, playing in quartets and octets, and in the BBC Elstree Concert Band where she is the General Manager. She is also a Liveryman of the Worshipful Company of Fletchers. Georgina was very honoured to be invited to the 2010 Women of the Year lunch as a Woman of Achievement.
Sir Walter Bodmer
Walter Bodmer studied mathematics at Cambridge University where, having become fascinated with genetics through courses taught by R A Fisher as part of the final year mathematics programme, he did his PhD with Fisher in population genetics. He then went as a Post Doctoral fellow in 1961 to work with Joshua Lederberg at Stanford University and to learn molecular biology. While there, eventually as a member of the Faculty for eight years, he initiated the work with his wife, Julia Bodmer, and with Rose Payne, which contributed to the discovery of the HLA system, and also his long standing involvement with somatic cell genetics. In 1970 Walter Bodmer returned to the UK to take up the chair of genetics at Oxford. In 1979 he left Oxford to become Director of Research at the Imperial Cancer Research Fund Laboratories in London and was appointed the first Director-General of the Fund in 1991. On retirement from the ICRF in 1996, he returned to Oxford University as Principal of Hertford college until 2005, and as head of the ICRF, now CRUK, Cancer and Immunogenetics laboratory at the Weatherall Institute of Molecular medicine where he continues his research. Walter Bodmer was one of the first to suggest the idea of the Human Genome Project and was first a Vice- President, and then the second President of HUGO. He has made major contributions to human population genetics, somatic cell genetics, the development of the HLA system and more recently to cancer genetics, especially as applied to colorectal cancer. Walter Bodmer was elected FRS in 1974, Knighted in 1986 for his contributions to science, is a Foreign Associate of the US National Academy of sciences and is the recipient of more than 30 honorary degrees and memberships and fellowships of scientific and medical societies.
Secretary, Sarasin & Partners
Andrew Hall worked as both a banker and an investment manager for Barclays Bank, before spending ten years with Royal Trust Co. of Canada. After a period as Managing Director of a new company in the Isle of Man he returned as associate director of Royal Trust in London. In 1980 he moved to Aitken Hume Ltd. as investment director. He joined Sarasin Investment Management in 1985 as a director with responsibility for expanding investment services, and was appointed Managing Director in 1989. In March 2002 he was appointed Executive Deputy Chairman and is now partner.
Mr Lewisohn was appointed an executive director of S. G. Warburg in 1969 and Deputy Chairman from 1987-1994. He is Chairman of Soditic Limited, the London subsidiary of the Soditic investment banking group where he has his office. He is registered with the Financial Conduct Authority (FCA), London. He is a director of Soditic Financial Services Ltd, Jersey and Fineurop Soditic S.p.A., Milan. He is also a Director of Bank Winter, Vienna. He is a member of the Advisory Board of The Official Monetary and Financial Institutions Forum (OMFIF). Mr Lewisohn is a ‘Founder’ Member of Cancer Research UK. He is a Trustee of EORTC Cancer Research Fund AISBL, Brussels and a Governor of the Yehudi Menuhin School, Cobham. He is an Honorary Member of Christ’s College, Cambridge, a Fellow of the Chartered Institute of Bankers, now The London Institute of Banking and Finance. A Liveryman of the Worshipful Company of International Bankers and Freeman of the Worshipful Company of Musicians. Mr Lewisohn is a Knight of the Order of Dannebrog, R1, Denmark.
Professor Sir Alex Markham
University of Leeds & 1980 Foulkes Fellow
Alex Markham completed a Chemistry PhD at the University of Birmingham in 1974 and has undertaken postdoctoral work in Japan, London, Cambridge (UK) and Boston (USA). He entered the commercial sector and had some 15 years’ experience in the pharmaceutical and diagnostics industries in both the UK and the USA, with GD Searle and then ICI Pharmaceuticals (now Astra Zeneca). His commercial experience includes both drug development (Gefitinib) and the worldwide introduction of DNA Fingerprinting for forensic and medico-legal applications. This was recognised by the Queen’s Award for Technological Achievement in 1990. He has made contributions to medical science in various fields. On the basis of his expertise in nucleic acid chemistry, he developed research programmes in medicinal chemistry then molecular biology from the mid ‘70s and was one of the pioneers of molecular genetics research in the UK in the 1980s. For the last 17 years in Leeds, his group has studied autosomal recessive Mendelian disorders in the highly inbred, immigrant communities of West Yorkshire, leading to an understanding of the causes of a variety of inherited neuro-developmental and malignant diseases. He qualified clinically in 1985, training at London and Oxford, and is accredited in pathology and internal medicine. He is the Professor of Medicine in the University of Leeds and directed the Molecular Medicine Institute at St James’s University Hospital. He has undertaken a range of administrative duties at national and international level, including the chairmanship/membership of numerous committees for the Medical Research Council, the Department of Health and the Wellcome Trust, and the International Agency for Research on Cancer (IARC), the Deutsche Krebshilfe, the Singapore Government Agency for Science Technology and Research (A-STAR), the Li Ka Shing Institute of the Chinese University of Hong Kong and the American Association for Cancer Research. A Fellow of the Academy of Medical Sciences and a Board Director of the International Union against Cancer (UICC), he was, until recently, chairman of the National Cancer Research Institute (NCRI). He continues to chair the NCRI Informatics Initiative and the National Cancer Intelligence Network. He has been a founder member of the UK Clinical Research Collaboration (UKCRC) Board and the National Institute of Health Research Advisory Board. He remains a member of the Government’s Cancer Reform Strategy (2007) Advisory Board, and chaired its Clinical Outcomes Group. Alex was Chief Executive of Cancer Research UK for 4 years from 2003-2007. He then returned to academic work at Leeds University but continues as Senior Medical Advisor to CR-UK. He serves on the Department of Health Ministerial/Industry Strategy Group and is Chairman of the Office for Strategic Coordination of Health Research (OSCHR), Translational Medicine Board. He is also the Department of Health Senior Responsible Owner and Board Chairman of the ‘Research Capability Programme’ in NHS “Connecting for Health” and Chairman of the Arthritis Research Campaign Scientific Strategy Committee. He was knighted for ‘Services to Medicine and to Healthcare’ in the Queen’s 2008 New Year Honours List.
Professor Colin Self
University of Newcastle upon Tyne & 1977 Foulkes Fellow
Professor Self’s career started with a Chemistry degree followed by a PhD in Metabolic Biochemistry. He carried out research in Immunology in the USA and in Germany and wrote a book on Immunology. He then took a medical degree at Cambridge University during which his research led to one of the first successful Cambridge biotechnology companies – IQ(Bio) Ltd. After hospital appointments in Cambridge he continued his clinical research at Hammersmith Hospital before being appointed to the Chair in Clinical Biochemistry at Newcastle University and heading the joint University-NHS Department. He remains very active in research in areas such as the development of next generation high performance diagnostic systems and, in therapeutics, the development of technology that allows antibodies to be made light dependent such that they are active only in those regions where they are required in the body.
Professor Sir John Tooke
John Tooke, Executive Chairman and Founder of Academic Health Solutions, has 20 years' experience of developing and leading successful academic health alliances – his ambition is to see health systems throughout the world benefiting from creative and enduring alliances with academia that drive health and wealth gain for the population served. A clinician scientist with interests in diabetes and vascular medicine, John led from inception the Peninsula Medical School, the first new Medical School in the UK for 40 years which graduated its first students in 2007. Until August 2015, he led the School of Life and Medical Sciences at UCL, London, as Vice Provost (Health) and Academic Director of UCLPartners, an academic health science system that subserves a population of 6m. Under his leadership, UCL achieved the status of arguably the most powerful biomedical research grouping in the UK, and UCLPartners is having material impact on the health of the local population. John is the immediate Past President of the Academy of Medical Sciences in the UK and continues to lead a major workstream for the Academy on how society judges evidence on the risks and benefits of medicines. He is currently co-Chair of the Centre for the Advancement of Sustainable Medical Innovation, a joint institute between Oxford University and UCL. He is also Past-Chair of the UK's Medical Schools Council and the UK Health Education Advisory Committee.